Patients treated with IV-tPA had HT prevalence of 32% (95% CI 27–37) in contrast to 20% (95% CI 14–27) in the untreated group (OD 1.9; CI 1.7–2.1, p < 0.001). The gene discussed is PLAT; the disease is hematocrit.